FR2407205A1 - Preparations pharmaceutiques contenant un derive d'uree a radical phenyle - Google Patents

Preparations pharmaceutiques contenant un derive d'uree a radical phenyle

Info

Publication number
FR2407205A1
FR2407205A1 FR7830328A FR7830328A FR2407205A1 FR 2407205 A1 FR2407205 A1 FR 2407205A1 FR 7830328 A FR7830328 A FR 7830328A FR 7830328 A FR7830328 A FR 7830328A FR 2407205 A1 FR2407205 A1 FR 2407205A1
Authority
FR
France
Prior art keywords
hydrogen
urea derivative
pharmaceutical preparations
preparations containing
bopi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7830328A
Other languages
English (en)
Other versions
FR2407205B1 (fr
Inventor
Karl Bernauer
Helmut Link
Harro Stohler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH546578A external-priority patent/CH642944A5/de
Priority claimed from CH546678A external-priority patent/CH639846A5/de
Priority claimed from CH940778A external-priority patent/CH644850A5/de
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of FR2407205A1 publication Critical patent/FR2407205A1/fr
Application granted granted Critical
Publication of FR2407205B1 publication Critical patent/FR2407205B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

L'INVENTION CONCERNE UN PRODUIT CHIMIQUE NOUVEAU. IL S'AGIT D'UNE PREPARATION PHARMACEUTIQUE CARACTERISEE EN CE QU'ELLE CONTIENT UN DERIVE D'UREE DE FORMULE GENERALE: (CF DESSIN DANS BOPI) OU R REPRESENTE UN HALOGENE, UN TRIFLUOROMETHYLE, UN NITRO OU UN ALCOXY INFERIEUR, R UN HYDROGENE, UN HALOGENE, UN TRIFLUORO-METHYLE, UN NITRO OU UN ALCOXY INFERIEUR, ET R UN HYDROGENE, UN HALOGENE OU UN TRIFLUOROMETHYLE, OU R, R ET R SONT EN POSITION META OU PARA PAR RAPPORT AU RADICAL R; ET OU EN OUTRE R REPRESENTE UN GROUPE DE FORMULE: (CF DESSIN DANS BOPI) OU R REPRESENTE UN ALCOYLE INFERIEUR, X UN OXYGENE OU UN IMINO, R UN ALCOYLE INFERIEUR ET R UN HYDROGENE OU UN ALCOYLE INFERIEUR, EN PRECISANT QUE: A. SI R REPRESENTE UN HYDROGENE ET R LE GROUPE B AVEC R EL'UN DES GROUPES: (CF DESSIN DANS BOPI) R REPRESENTE UN HYDROGENE OU UN ALCOYLE EN C A C. CE COMPOSE EST UTILE COMME MEDICAMENT.
FR7830328A 1977-10-28 1978-10-25 Preparations pharmaceutiques contenant un derive d'uree a radical phenyle Granted FR2407205A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
LU78407 1977-10-28
LU78408 1977-10-28
CH546578A CH642944A5 (en) 1978-05-19 1978-05-19 Urea derivatives
CH546678A CH639846A5 (en) 1978-05-19 1978-05-19 Pharmaceutical preparations having antiandrogenic action, containing urea derivatives or hydantoin derivatives
CH940778A CH644850A5 (en) 1977-10-28 1978-09-07 Pharmaceutical preparations containing urea derivatives

Publications (2)

Publication Number Publication Date
FR2407205A1 true FR2407205A1 (fr) 1979-05-25
FR2407205B1 FR2407205B1 (fr) 1982-12-31

Family

ID=27509239

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7830328A Granted FR2407205A1 (fr) 1977-10-28 1978-10-25 Preparations pharmaceutiques contenant un derive d'uree a radical phenyle

Country Status (15)

Country Link
US (1) US4234736A (fr)
JP (1) JPS5473754A (fr)
AU (2) AU522796B2 (fr)
BE (1) BE871584A (fr)
BR (1) BR7807115A (fr)
CA (2) CA1138334A (fr)
DE (1) DE2846945A1 (fr)
DK (1) DK481778A (fr)
FR (1) FR2407205A1 (fr)
GB (2) GB2008101B (fr)
IL (1) IL55774A (fr)
IT (1) IT1100904B (fr)
NL (1) NL7810562A (fr)
NZ (1) NZ188720A (fr)
SE (2) SE433304B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0017976A2 (fr) * 1979-04-24 1980-10-29 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Procédé de préparation de dérivés d'imidazole

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC1220A1 (fr) * 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
DE3382406D1 (de) * 1982-04-08 1991-10-17 Shell Int Research Neue hydantoine, ihre herstellung und verwendung.
AU636853B2 (en) * 1988-08-23 1993-05-13 Nutrasweet Company, The Substituted aryl ureas as high potency sweeteners
FR2656302B1 (fr) * 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
USRE35956E (en) * 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US5670641A (en) * 1995-06-02 1997-09-23 American Cyanamid Company 3-(3-aryloxyphenyl)-1-(substituted methyl)-S-triazine-2,4,6-oxo or thiotrione herbicidal agents
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
AU8821301A (en) 2000-06-28 2002-01-08 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, design and use
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (fr) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Composés de succinimide hétérocyclique fondu et leurs analogies, modulateurs de la fonction de récepteur d'hormone nucléaire
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
ATE404544T1 (de) 2001-12-19 2008-08-15 Bristol Myers Squibb Co Kondensierte heterocyclische verbindungen und deren analoga; modulatoren der funktion von nukleären hormonrezeptoren
ATE502298T1 (de) * 2003-12-19 2011-04-15 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
US7718684B2 (en) * 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
ES2593379T3 (es) 2006-03-27 2016-12-09 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
JP5350217B2 (ja) * 2006-03-29 2013-11-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジアリールチオヒダントイン化合物
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
CN104661658A (zh) 2012-09-26 2015-05-27 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN111479560A (zh) 2017-10-16 2020-07-31 阿拉贡药品公司 用于治疗非转移性去势难治性前列腺癌的抗雄激素

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE629779A (fr) *
US3134663A (en) * 1957-07-23 1964-05-26 Geigy Chem Corp Herbicidal composition and method employing hydantoins
GB997037A (en) 1962-03-19 1965-06-30 Ici Ltd New hydrantoin derivatives
IL31416A0 (en) 1968-02-19 1969-03-27 Bayer Ag 5-imino-2-oxo-imidazolidines,their preparation and use as herbicides
NO124370B (fr) * 1968-03-28 1972-04-10 Ciba Geigy Ag
DK123717B (da) * 1968-11-25 1972-07-24 Sumitomo Chemical Co 3-(3',5'-Dihalogenphenyl)-imidazolidin-2,4-dionderivater med mirobicid virkning.
US3676456A (en) * 1970-02-27 1972-07-11 Ciba Geigy Corp Derivatives of 3-aryl-5-alkylhydantoins
JPS5136332B1 (fr) * 1970-12-09 1976-10-07
US4044021A (en) * 1971-10-21 1977-08-23 American Cyanamid Company Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism
IL45459A (en) 1973-09-03 1978-01-31 Ciba Geigy Ag 1-(dichlorofluoromethylthio)-3-phenyl-imidazolidine-2,4-dione derivatives their preparation and their use as bactericides and fungicides
FR2329276A1 (fr) * 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0017976A2 (fr) * 1979-04-24 1980-10-29 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Procédé de préparation de dérivés d'imidazole
EP0017976A3 (en) * 1979-04-24 1981-04-01 F. Hoffmann-La Roche & Co. Aktiengesellschaft Process for preparing imidazole derivatives and the starting materials used in this process

Also Published As

Publication number Publication date
GB2087870B (en) 1982-11-10
AU522796B2 (en) 1982-06-24
NZ188720A (en) 1984-12-14
IT7829207A0 (it) 1978-10-27
SE8202106L (sv) 1982-04-01
GB2008101A (en) 1979-05-31
GB2087870A (en) 1982-06-03
IT1100904B (it) 1985-09-28
BE871584A (fr) 1979-04-27
AU8105182A (en) 1982-07-08
FR2407205B1 (fr) 1982-12-31
IL55774A (en) 1982-04-30
CA1137091A (fr) 1982-12-07
IL55774A0 (en) 1978-12-17
NL7810562A (nl) 1979-05-02
GB2008101B (en) 1982-09-08
SE7811193L (sv) 1979-04-29
JPS5473754A (en) 1979-06-13
CA1138334A (fr) 1982-12-28
AU4096278A (en) 1980-05-01
BR7807115A (pt) 1979-05-15
US4234736A (en) 1980-11-18
SE433304B (sv) 1984-05-21
DK481778A (da) 1979-04-29
AU551161B2 (en) 1986-04-17
DE2846945A1 (de) 1979-05-03

Similar Documents

Publication Publication Date Title
FR2407205A1 (fr) Preparations pharmaceutiques contenant un derive d'uree a radical phenyle
RU95113480A (ru) Новые аналоги витамина d, способы получения, фармацевтическая композиция, способ лечения
NO170280C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfamatderivater
CA2102454A1 (fr) Derives de l'erythromycine, leur procede de preparation, leur application comme medicaments
BE903183A (fr) Nouveaux derives du benzonorbornene, leurs procedes de preparation et composition medicamenteuse et cosmetique les contenant
CA2013324A1 (fr) Pteridin-4 (3h)-ones, procedes de preparation et medicaments les contenant
DK165109C (da) 4-anilino-cyklopentaoedaapyrimidinderivater samt farmaceutiske midler indeholdende saadanne
GB1445503A (en) Acylamino acid amides
FR2363326A1 (fr) Traitement de l'affection dermatologique dite " peau seche "
FR2457689A1 (fr) Medicament hypolipemique a base de carnitine
KR880003626A (ko) 레트로비루스로 감염된 환자의 치료에 있어서의 2',3'-디디옥시사이티딘-2'-엔(2',3'-디디옥시-2',3'-디디하이드로사이티딘)의 사용법
RU94026094A (ru) Применение феналкиламинов
FR2358415A1 (fr) Derives peptidiques, leur preparation et leur application en tant que medicaments
MA24668A1 (fr) Derives de 4-amino-2 (5h)- furanones et de 4-amino-2-(5h)-thiophenones en tant qu'agentsanti-tumeurs
FR2368959A1 (fr) Compositions contenant des derives de l'acide guanidinoalcanoique, utilisables comme medicament
ATE72447T1 (de) Chartreusinderivate und salze, diese enthaltende antitumorzusammensetzungen und verfahren zu ihrer herstellung.
RU94046463A (ru) Антиандрогенное соединение, предшественник лекарственного средства, фармацевтические композиции, способ лечения или предотвращения заболеваний
Singh et al. Some unusual acid-catalyzed rearrangements of glycidic esters
FR2453152A1 (fr) Nouveaux derives de prostaglandine et medicament les contenant
KR900011724A (ko) 특정 피롤릴페닐-치환된 하이드록삼산 유도체
ATE110568T1 (de) Pharmazeutisches präparat zur behandlung des katarakts.
FR2407941A1 (fr) Nouveaux derives de cholesterol
BE904865A (fr) Derives du phenanthrene, leur procede de preparation et compositions fongicides les contenant.
FR2450837A1 (fr) Acides penicillaniques 6-b-substitues inhibiteurs de b-lactamase, leur procede de production et composition pharmaceutique les contenant
FR2603580A1 (fr) Procede de preparation d'un compose organique polyfluorure

Legal Events

Date Code Title Description
ST Notification of lapse